JP2014511877A - ポロ様キナーゼ１ポロ−ボックスドメインのペプチド模倣リガンド及び使用方法 - Google Patents

ポロ様キナーゼ１ポロ−ボックスドメインのペプチド模倣リガンド及び使用方法 Download PDF

Info

Publication number
JP2014511877A
JP2014511877A JP2014505275A JP2014505275A JP2014511877A JP 2014511877 A JP2014511877 A JP 2014511877A JP 2014505275 A JP2014505275 A JP 2014505275A JP 2014505275 A JP2014505275 A JP 2014505275A JP 2014511877 A JP2014511877 A JP 2014511877A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014505275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511877A5 (enExample
Inventor
テレンス アール．， ジュニア バーク，
ウェンジャン キアン，
ファ リウ，
キュン エス． リー，
ジュンユン パク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government Of United States, REPRESENTED BY SECRETARY Department Of Health And Human Services AS
Original Assignee
Government Of United States, REPRESENTED BY SECRETARY Department Of Health And Human Services AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of United States, REPRESENTED BY SECRETARY Department Of Health And Human Services AS filed Critical Government Of United States, REPRESENTED BY SECRETARY Department Of Health And Human Services AS
Publication of JP2014511877A publication Critical patent/JP2014511877A/ja
Publication of JP2014511877A5 publication Critical patent/JP2014511877A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11021—Polo kinase (2.7.11.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2014505275A 2011-04-12 2012-04-12 ポロ様キナーゼ１ポロ−ボックスドメインのペプチド模倣リガンド及び使用方法 Pending JP2014511877A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161474621P 2011-04-12 2011-04-12
US61/474,621 2011-04-12
US201261588470P 2012-01-19 2012-01-19
US61/588,470 2012-01-19
PCT/US2012/033259 WO2012142245A2 (en) 2011-04-12 2012-04-12 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Publications (2)

Publication Number Publication Date
JP2014511877A true JP2014511877A (ja) 2014-05-19
JP2014511877A5 JP2014511877A5 (enExample) 2015-05-28

Family

ID=46147674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505275A Pending JP2014511877A (ja) 2011-04-12 2012-04-12 ポロ様キナーゼ１ポロ−ボックスドメインのペプチド模倣リガンド及び使用方法

Country Status (6)

Country Link
US (1) US10266565B2 (enExample)
EP (1) EP2686342A2 (enExample)
JP (1) JP2014511877A (enExample)
AU (1) AU2012242784B2 (enExample)
CA (1) CA2832073A1 (enExample)
WO (1) WO2012142245A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206344A1 (ja) * 2024-03-28 2025-10-02 日産化学株式会社 グラフェンリンカー化合物及び電界効果トランジスタバイオセンサー

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153101A2 (en) 2013-03-14 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
KR101672975B1 (ko) * 2014-07-03 2016-11-04 한국과학기술연구원 알로스테릭 ｐｌｋ1-ｐｂｄ 저해활성을 가지는 고리형 포스포펩티드 화합물
KR101650778B1 (ko) * 2014-10-17 2016-08-25 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 유효성분으로 포함하는 피임용 조성물
KR101670770B1 (ko) * 2014-10-17 2016-11-01 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 포함하는 항암용 조성물
WO2017082924A1 (en) 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
CN115873033B (zh) * 2022-12-28 2025-03-18 永农生物科学有限公司 一种草铵膦的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206344A1 (ja) * 2024-03-28 2025-10-02 日産化学株式会社 グラフェンリンカー化合物及び電界効果トランジスタバイオセンサー

Also Published As

Publication number Publication date
US10266565B2 (en) 2019-04-23
WO2012142245A8 (en) 2013-11-21
EP2686342A2 (en) 2014-01-22
WO2012142245A2 (en) 2012-10-18
US20140142044A1 (en) 2014-05-22
AU2012242784B2 (en) 2017-04-13
WO2012142245A3 (en) 2012-12-27
AU2012242784A1 (en) 2013-10-31
CA2832073A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
US10266565B2 (en) Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
US7943581B2 (en) Cell penetrating peptides for intracellular delivery of molecules
CA2632451A1 (en) Cell penetrating peptides for intracellular delivery of molecules
US10047122B2 (en) Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
EP4512426A1 (en) Compound and use thereof
CA3030855A1 (en) Methods and compositions relating to covalently circularized nanodiscs
US9175038B2 (en) Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
CA3079758A1 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
US20160046672A1 (en) STAPLING eIF4E INTERACTING PEPTIDES
AU2018302855B2 (en) Peptide derivative and pharmaceutical composition containing same
US20150246946A1 (en) Peptides and methods for treating cancer
EP1795539B1 (en) Cell penetrating peptides for intracellular delivery of molecules
US20130345115A1 (en) Nuclear penetrating h4 tail peptides for the treatment of diseases mediated by impaired or loss of p53 function
WO2018085836A1 (en) Anti-hiv peptides
US8916679B2 (en) Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
CA3249979A1 (en) Compound and use thereof
Class et al. Patent application title: PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE Inventors: Wenjian Qian (Frederick, MD, US) Jung Eun Park (Bethesda, MD, US) Christopher C. Lai (Ellicott City, MD, US) James A. Kelley (Silver Spring, MD, US) Kyung S. Lee (Gaithersburg, MD, US) Terrence R. Burke, Jr.(Bethesda, MD, US)
WO2022232567A2 (en) Cyclic peptide inhibitors of usp22

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171002